Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992977 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
A Phase 1 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02992977: Clinical Trial Phase 1 study, sponsored by Agenus.
NCT02992977 is a Phase 1 study that was terminated before completion, run by Agenus. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02992977, a Phase 1 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
Primary Outcome
AEs, irAEs, according to NCI CTCAE version 4.03.
Interventions
- BIOLOGICAL AutoSynVax™ vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Why NCT02992977 stopped before completion
NCT02992977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which AutoSynVax™ vaccine is the first listed.
NCT02992977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02992977 about?
NCT02992977 is a clinical study titled "Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer". Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
What is the current status of trial NCT02992977?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02992977?
The interventions under investigation include: AutoSynVax™ vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02992977?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02992977's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia